Female After Care Daily
Natural health product licensed in Canada
- Other names
- Female Hormone Care Daily
- Licence holder
- Red Maple Bio Inc.
- NPN or DIN-HM
- 80107320
- Status
- Active licence
- Licence date
- 15 January 2021
- Revision date
- 6 February 2025
- Form
- Capsule
- Route of administration
- Orale
- Application type
- Non traditionnelle
If this product were sold in France
- Dose déclarée au-delà d'une limite
Zinc: up to 50 mg a day according to the dosing instructions published by Health Canada (2 unités posologiques par jour au plus, pour les adultes), above the maximum dose of 15 mg set in France for a food supplement (2006 Order, not revised since November 2006).
arrêté du 9 mai 2006, annexe III. French orders of 9 May 2006 and 14 November 2006 as published in the Official Journal (maximum daily doses), retrieved 21 October 2026.
- À vérifier
Zinc: up to 50 mg a day according to the dosing instructions published by Health Canada, above the limite de sécurité from EFSAEuropean Food Safety Authority. for adults (25 mg a day). Le repère de l'EFSA porte sur l'apport total d'une journée, alimentation et compléments.
limite supérieure de sécurité (UL). EFSA, Overview on Tolerable Upper Intake Levels (version 11, August 2025), retrieved 21 October 2026.
- Conditions légales
Vitex agnus-castus L.: L'étiquetage doit comporter un avertissement déconseillant l'usage chez les femmes ayant des antécédents personnels ou familiaux de cancer du sein.
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
- Conditions légales
Actaea racemosa L.: Seuls les extraits aqueux et hydro-alcooliques de titre faible (30 %) sont admis. La portion journalière recommandée ne doit pas conduire à une ingestion de glycosides de triterpène (calculés comme 27-déoxyactéine) supérieure à 3 mg.
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Vitamine C Source : Acide ascorbique | 15 mg | 30,000 µg |
| Calcium Source : Calcium carbonate | 12.5 mg | 25,000 µg |
| Vitex agnus-castus Source : Fruit Extract : Matériel brut sec Extraction ratio : 10:1 Dry plant equivalent : 500 mg | 50 mg | Not calculated |
| Folate Source : Acide folique | 0.2 Microgrammes | Not calculated |
| Vitamine E Source : Acétate de dl-alpha tocophéryle | 10 mg AT | Not calculated |
| Rubus idaeus Source : Feuille Extract : Matériel brut sec Extraction ratio : 10:1 Dry plant equivalent : 500 mg | 50 mg | Not calculated |
| Vitamine B12 Source : Hydroxocobalamine | 25 Microgrammes | Not calculated |
| Actaea racemosa Source : Racine et rhizome Extract : Matériel brut sec Extraction ratio : 30:1 Dry plant equivalent : 750 mg | 25 mg | Not calculated |
| Vitamine A Source : Palmitate de vitamine A | 82.5 microgram RAE | Not calculated |
| Niacine Source : Niacinamide | 15 mg | Not calculated |
| Withania somnifera Source : Racine Extract : Matériel brut sec Extraction ratio : 10:1 Dry plant equivalent : 1,000 mg | 100 mg | Not calculated |
| Zinc Source : Oxyde de zinc | 25 mg | 50,000 µg |
Non-medicinal ingredients
Cellulose microcristalline, Dioxyde de silicium, Gélatine, Stéarate de magnésium
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | minimum: 19 years | 1 Capsule | 2 Tous les jours |
Uses authorised in Canada
Text supplied in English because no French text is available.
Helps to support/promote healthy estrogen metabolism/balance. Helps in wound healing and connective tissue formation. Chaste Berry is used in Herbal Medicine (as a hormone normalizer) to help stabilize menstrual cycle irregularities and relieve premenstrual symptoms. Ashwagandha is traditionally used in Ayurveda as Rasayana (rejuvenative tonic). Ashwagandha is traditionally used in Ayurveda to relieve general debility, especially during convalescence or old age. Black Cohosh is used in Herbal Medicine to help relieve the pain associated with menstruation as well as premenstrual symptoms. Black Cohosh is traditionally used in Herbal Medicine to help ease nervous tension (calmative). Helps to maintain immune function. Helps to maintain the body's ability to metabolize nutrients. Source of vitamins and minerals, factors in the maintenance of good health. Source of vitamins and minerals, factors in normal growth and development. Source of vitamins and minerals to support biological functions which play a key role in the maintenance of good health. Source of antioxidant that helps to protect cell against the oxidative damage caused by free radicals.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
No French warning text available in the imported data.
Warnings are available in English on the official record.
Source
Official Health Canada record, licence 80107320
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- Vitex agnus-castus
Read the warning, when it applies and the studies cited
CHASTE TREE - VITEX AGNUS-CASTUS
Route of administration: Oral (WHO 2009; Bradley 2006; Mills and Bone 2000)
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking hormone-containing medications such as progesterone preparations, oral contraceptives or hormone replacement therapy (Brinker 2010; WHO 2009; Bradley 2006).
3 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
Contraindications
Do not use if you are pregnant, breastfeeding or attempting to conceive unless you have consulted with a health care practitioner/health care provider/health care professional/doctor/physician (EMA 2018; Najib et al. 2022; Brinker 2010; WHO 2009; Dugoua et al. 2008; ESCOP 2003; Blumenthal 2000; Mills and Bone 2000).
8 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
- Actaea racemosa
Read the warning, when it applies and the studies cited
Black Cohosh - Actaea Racemosa
Route of administration: Oral
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are breastfeeding.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a liver disorder or develop symptoms of liver trouble (EMA 2018, 2007; Lynch et al. 2006; Mills et al. 2006; Cohen et al. 2004; NIH 2004).
6 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
Contraindications
Do not use if you are pregnant (Brinker 2010; Hoffmann 2003; Tilgner 1999).
3 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
- Withania somnifera
Read the warning, when it applies and the studies cited
ASHWAGANDHA - WITHANIA SOMNIFERA
Route of administration: Oral
Cautions and warnings
Condition of application: General debility; Memory enhancement; Adaptogen; Restlessness/nervousness.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Condition of application: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Upton 2000; McGuffin et al. 1997).
2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).
When using this product exercise caution if you drive or use machinery as you may experience drowsiness (Berardi et al. 2002).
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
They concern the ingredient, not this product or its dose. They do not replace medical advice.
List in the official revision dated (register: Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks).
Has the product changed? Photograph the packaging.
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.